Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$4.28 -7.8%	$4.68	$2.14 ▼ $6.82	$183.42M	1.5	76,693 shs	93,883 shs
GOSS Gossamer Bio	$0.88 +0.6%	$1.09	$0.50 ▼ $1.55	$200.34M	1.88	1.57 million shs	585,824 shs
IVA Inventiva	$3.81 +0.1%	$3.14	$1.53 ▼ $4.05	$199.68M	0.84	62,670 shs	1,152 shs
PRLD Prelude Therapeutics	$0.90 +1.6%	$0.75	$0.61 ▼ $6.80	$50.86M	1.35	267,440 shs	52,754 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	+14.85%	+31.44%	+21.47%	-22.02%	+80.54%
GOSS Gossamer Bio	-8.55%	+7.80%	-25.09%	-4.82%	+31.20%
IVA Inventiva	-2.72%	+6.29%	+29.10%	+72.00%	+16.43%
PRLD Prelude Therapeutics	-1.59%	+11.01%	+10.87%	-22.23%	-78.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DMAC DiaMedica Therapeutics	1.7321 of 5 stars	3.5	2.0	0.0	3.3	0.0	0.0
GOSS Gossamer Bio	3.9907 of 5 stars	3.5	2.0	4.7	3.6	1.7	0.0
IVA Inventiva	1.9586 of 5 stars	3.4	1.0	0.0	2.6	1.7	0.6
PRLD Prelude Therapeutics	2.937 of 5 stars	3.2	2.0	0.0	2.6	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMAC DiaMedica Therapeutics	3.00	Buy	$8.00	86.92% Upside
GOSS Gossamer Bio	3.00	Buy	$7.50	750.63% Upside
IVA Inventiva	2.80	Moderate Buy	$10.40	173.32% Upside
PRLD Prelude Therapeutics	2.33	Hold	$4.00	344.00% Upside

Current Analyst Ratings Breakdown

Latest PRLD, GOSS, DMAC, and IVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/29/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$4.00 ➝ $4.00
4/17/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
4/8/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/4/2025	IVA Inventiva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $9.00
3/28/2025	IVA Inventiva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
3/19/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
3/18/2025	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/14/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
2/21/2025	IVA Inventiva	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
1/30/2025	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
1/30/2025	IVA Inventiva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
GOSS Gossamer Bio	$114.70M	1.75	N/A	N/A	$0.28 per share	3.15
IVA Inventiva	$9.20M	21.71	N/A	N/A	($0.67) per share	-5.68
PRLD Prelude Therapeutics	$7M	7.27	N/A	N/A	$4.32 per share	0.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMAC DiaMedica Therapeutics	-$19.38M	-$0.60	N/A	N/A	N/A	N/A	-43.67%	-40.81%	5/6/2025 (Estimated)
GOSS Gossamer Bio	-$179.82M	-$0.26	N/A	N/A	N/A	N/A	-127.28%	-22.12%	5/6/2025 (Estimated)
IVA Inventiva	-$119.51M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	-$121.83M	-$1.69	N/A	N/A	N/A	N/A	-66.89%	-55.59%	5/6/2025 (Estimated)

Latest PRLD, GOSS, DMAC, and IVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	N/A	N/A	N/A	N/A	N/A
5/6/2025	Q1 2025	GOSS Gossamer Bio	-$0.19	N/A	N/A	N/A	$3.95 million	N/A
5/6/2025	Q1 2025	PRLD Prelude Therapeutics	-$0.48	N/A	N/A	N/A	N/A	N/A
3/18/2025	Q4 2024	GOSS Gossamer Bio	-$0.15	-$0.15	N/A	-$0.15	$7.02 million	$9.38 million
3/17/2025	Q4 2024	DMAC DiaMedica Therapeutics	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A
3/10/2025	Q4 2024	PRLD Prelude Therapeutics	-$0.49	-$0.38	+$0.11	-$0.38	N/A	$4.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMAC DiaMedica Therapeutics	N/A	11.81	11.81
GOSS Gossamer Bio	3.64	6.74	6.74
IVA Inventiva	N/A	0.59	0.59
PRLD Prelude Therapeutics	N/A	7.04	7.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMAC DiaMedica Therapeutics	10.12%
GOSS Gossamer Bio	81.23%
IVA Inventiva	19.06%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
DMAC DiaMedica Therapeutics	7.30%
GOSS Gossamer Bio	5.00%
IVA Inventiva	32.00%
PRLD Prelude Therapeutics	62.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMAC DiaMedica Therapeutics	20	42.86 million	39.68 million	Optionable
GOSS Gossamer Bio	180	227.22 million	215.27 million	Optionable
IVA Inventiva	100	52.48 million	35.68 million	Not Optionable
PRLD Prelude Therapeutics	120	56.45 million	20.47 million	Optionable

PRLD, GOSS, DMAC, and IVA Headlines

Recent News About These Companies

Prelude Therapeutics (NASDAQ:PRLD) and Dianthus Therapeutics (NASDAQ:DNTH) Head-To-Head Analysis

April 28 at 2:09 AM | americanbankingnews.com

Prelude Announces Presentations at 2025 AACR Annual Meeting

April 25, 2025 | globenewswire.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know

April 10, 2025 | zacks.com

Prelude Therapeutics Founder Acquires 28% More Stock

March 29, 2025 | finance.yahoo.com

Prelude Therapeutics CEO buys $467K in common stock

March 28, 2025 | markets.businessinsider.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $69,000.00 in Stock

March 28, 2025 | insidertrades.com

Prelude Therapeutics stock surges on insider buying

March 27, 2025 | investing.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 Shares

March 15, 2025 | insidertrades.com

Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements

March 14, 2025 | msn.com

Analysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)

March 12, 2025 | markets.businessinsider.com

Barclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD)

March 12, 2025 | markets.businessinsider.com

Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)

March 10, 2025 | markets.businessinsider.com

Prelude Therapeutics sees cash runway into 2Q26

March 10, 2025 | markets.businessinsider.com

Prelude Therapeutics Reports Positive Clinical Results for SMARCA2 Degrader PRT3789 in Phase 1 Trials and Provides Financial Update

March 10, 2025 | quiverquant.com

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

March 10, 2025 | globenewswire.com

Prelude Therapeutics to Present at Barclays Global Healthcare Conference

March 6, 2025 | msn.com

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

March 5, 2025 | globenewswire.com

Insider Buying: Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Acquires 10,000 Shares of Stock

January 3, 2025 | insidertrades.com

Andrew Combs Acquires 60,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock

December 27, 2024 | insidertrades.com

Prelude Therapeutics Inc (PRLD) Stock Trading Recap

December 24, 2024 | bovnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD, GOSS, DMAC, and IVA Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

$4.28 -0.36 (-7.76%)

Closing price 04:00 PM Eastern

Extended Trading

$4.28 0.00 (-0.12%)

As of 04:05 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Gossamer Bio NASDAQ:GOSS

$0.88 +0.01 (+0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$0.90 +0.02 (+2.30%)

As of 06:50 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Inventiva NASDAQ:IVA

$3.71 -0.09 (-2.37%)

As of 04:00 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Prelude Therapeutics NASDAQ:PRLD

$0.90 +0.02 (+1.96%)

As of 04:00 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time